Edwards Lifesciences Corporation (EW)
| Market Cap | 52.80B +15.8% |
| Revenue (ttm) | 6.51B +14.6% |
| Net Income | 1.00B -75.8% |
| EPS | 1.72 -75.5% |
| Shares Out | 576.40M |
| PE Ratio | 54.65 |
| Forward PE | 29.17 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,852,610 |
| Open | 92.92 |
| Previous Close | 92.56 |
| Day's Range | 91.48 - 92.92 |
| 52-Week Range | 72.30 - 96.29 |
| Beta | 0.85 |
| Analysts | Buy |
| Price Target | 100.96 (+10.22%) |
| Earnings Date | Jul 23, 2026 |
About EW
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aor... [Read more]
Financial Performance
In 2025, Edwards Lifesciences's revenue was $6.07 billion, an increase of 11.55% compared to the previous year's $5.44 billion. Earnings were $1.07 billion, a decrease of -74.28%.
Financial StatementsAnalyst Summary
According to 28 analysts, the average rating for EW stock is "Buy." The 12-month stock price target is $100.96, which is an increase of 10.22% from the latest price.
News
Edwards Lifesciences upgraded to Buy from Neutral at UBS
UBS upgraded Edwards Lifesciences (EW) to Buy from Neutral with a price target of $110, up from $90, after assuming coverage of the name. Edwards Lifesciences is entering a new…
Edwards Lifesciences price target raised to $105 from $100 at JPMorgan
JPMorgan raised the firm’s price target on Edwards Lifesciences (EW) to $105 from $100 and keeps an Overweight rating on the shares.
Leerink upgrades Edwards Lifesciences to Outperform, raises target to $101
As previously reported, Leerink upgraded Edwards Lifesciences (EW) to Outperform from Market Perform with a price target of $101, up from $87. The firm says it has seen “enough to…
Edwards Lifesciences price target raised to $101 from $100 at Piper Sandler
Piper Sandler raised the firm’s price target on Edwards Lifesciences (EW) to $101 from $100 and keeps an Overweight rating on the shares. The firm notes the company reported strong…
Edwards Lifesciences upgraded to Outperform from Market Perform at Leerink
Leerink analyst Mike Kratky upgraded Edwards Lifesciences (EW) to Outperform from Market Perform with a $101 price target
Edwards Lifesciences beats quarterly estimates on strong demand for heart devices
Edwards Lifesciences beat analysts' estimates for second-quarter profit and revenue on Thursday, helped by strong demand for its artificial heart valves used in complex cardiac procedures, sending i...
Edwards Lifesciences Narrows Full-Year Sales Outlook After Second-Quarter Growth
The medical-technology company said it now expects sales of $6.6 billion to $6.9 billion for the full year, raising the bottom end of its prior range of $6.5 billion to $6.9 billion.
Edwards Lifesciences Earnings Call Transcript: Q2 2026
Q2 sales grew 12.5% year-over-year, driven by strong TAVR and TMTT performance, leading to raised 2026 sales guidance and reaffirmed EPS outlook. Robust adoption of innovative therapies and favorable market dynamics support confidence in long-term 10% average sales growth.
Edwards Lifesciences Earnings release: Q2 2026
Edwards Lifesciences released its Q2 2026 earnings on July 23, 2026, summarizing the period's financial results.
Edwards Lifesciences Quarterly report: Q2 2026
Edwards Lifesciences has published its Q2 2026 quarterly earnings report on July 23, 2026.
Edwards Lifesciences reports Q2 EPS 78c, consensus 74c
Reports Q2 revenue $1.74B, consensus $1.70B. In the second quarter, the company reported TAVR sales of $1.3 billion, which grew 11.3% compared to the prior year, or 10.5% on a…
Edwards Lifesciences sees Q3 EPS 71c-77c, consensus 75c
Sees Q3 revenue $1.63B-$1.71B, consensus $1.69B
Edwards Lifesciences affirms FY26 EPS view of $2.95-$3.05, consensus $3.01
Narrows higher FY26 revenue growth view to 10%-11% from 9%-11%, consensus $6.74B. The company states: “Based on the company’s second quarter performance, Edwards is increasing its full-year 2026 sales...
Edwards Lifesciences up 4% at $87.50 after Q2 earnings beat and guidance
16:19 EDT Edwards Lifesciences (EW) up 4% at $87.50 after Q2 earnings beat and guidance
Edwards Lifesciences Reports Second Quarter Results
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended June 30, 2026. Highlights Q2 sales grew 13.6% to $1.74 billion1, constant curren...
Edwards Lifesciences price target raised to $95 from $90 at Truist
Truist analyst Richard Newitter raised the firm’s price target on Edwards Lifesciences (EW) to $95 from $90 and keeps a Hold rating on the shares as part of a broader…
Edwards Lifesciences to Host Earnings Conference Call on July 23, 2026
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2026 after the market closes on Thursday July 23, and will host ...
Edwards Lifesciences price target raised to $105 from $100 at Mizuho
Mizuho raised the firm’s price target on Edwards Lifesciences (EW) to $105 from $100 and keeps an Outperform rating on the shares. The firm adjusted targets in the medical device…
Edwards Lifesciences price target raised to $110 from $100 at RBC Capital
RBC Capital raised the firm’s price target on Edwards Lifesciences (EW) to $110 from $100 and keeps an Outperform rating on the shares as part of a broader research note…
Edwards Lifesciences price target raised to $110 from $101 at Citi
Citi raised the firm’s price target on Edwards Lifesciences (EW) to $110 from $101 and keeps a Buy rating on the shares. For Q2 earnings season, given “the skittish trading…
Did Edwards Lifesciences Corporation Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Edwards' Structural Heart Leadership Demonstrated Through Expanding Body of Scientific Evidence at New York Valves
NEW YORK--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new data presented at New York Valves 2026, the annual conference organized by the Cardiovascular Research Foundation, which ...
Pacific Defense Launches Dual-Enclave 100G Ethernet Switch for Secure Multi-Mission C5ISR and Electronic Warfare Systems
EL SEGUNDO, Calif.--(BUSINESS WIRE)--Pacific Defense today announced the launch of the SWH1530VP, a next-generation dual-enclave 100/40 Gigabit Ethernet switch engineered to provide secure, determinis...
East West Announces $858,000 Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - June 12, 2026) - East West Minerals Ltd. (TSXV: EW) ("East West" or the "Company") announces that further to a price reservation filed on June 10, 2026, ...
Edwards Lifesciences Transcript: Bank of America Global Healthcare Conference 2026
Strong Q1 results and increased guidance reflect broad-based growth in TAVR, surgical, and TMTT segments, supported by new clinical evidence and product innovation. Leadership changes and a robust pipeline position the company for sustained double-digit growth and margin improvement through 2027 and beyond.